Table 3.
Devices with potential to measure autoantibodies (Ab) at point-of-care
| Autoantibody | Detection technology/assay platform | Assay duration | References |
|---|---|---|---|
| Anti-dsDNA | Electrochemical reduction of redox-tagged probe/Ab inhibition in single-step cell | ~45 min | [60] |
| Decreased resonance frequency/piezoelectric quartz crystal microbalance | <60 min | [61] | |
| Refractive index change/surface plasmon resonance sensor chip | ~5 min | [62] | |
| Anti-CCP | Formation of visual line by colored nanoparticles/lateral flow chromatography | 10 min | [66] |
| Refractive index change/surface plasmon resonance sensor chip | ~5 min | [67] | |
| Anti-chromatin | Peroxidase-mediated electrochemical amplification/flow-through cell | 20 min | [64] |
| Anti-IgG (RF) Anti-MCV | Formation of visual line by colored nanoparticles/lateral flow chromatography | 15 min | [65] |
| Anti-Ro/SSA, Anti-Ro52, Anti-La/SSB | Luminescence by luciferase-tagged probe/bead immobilized Ab in two-step cells | 25 min | [63] |
| Anti-β2-glyco-protein I | Refractive index change/surface plasmon resonance sensor chip | ~5 min | [68] |